Copyright
        ©The Author(s) 2021.
    
    
        World J Nephrol. Mar 25, 2021; 10(2): 8-20
Published online Mar 25, 2021. doi: 10.5527/wjn.v10.i2.8
Published online Mar 25, 2021. doi: 10.5527/wjn.v10.i2.8
            Table 1 Patients’ characteristics and renal function (entire study cohort)
        
    | Total (n = 421) | Control (n = 342) | LMWD (n = 79) | P value | |
| Sex | ||||
| Male | 281 (66.7) | 219 (64.0) | 62 (78.5) | 0.017 | 
| Female | 140 (33.3) | 123 (36.0) | 17 (21.5) | |
| Age, yr | 75.0 [69.0, 80.0] | 76.0 [69.0, 80.0] | 74.0 [68.0, 79.0] | 0.178 | 
| Body mass index, kg/m2 | 24.0 [21.1, 26.2] | 23.9 [21.1, 26.0] | 24.4 [21.3, 26.6] | 0.273 | 
| Procedure | ||||
| Coronary angiography | 279 (66.3) | 238 (69.6) | 41 (51.9) | 0.004 | 
| PCI | 142 (33.7) | 104 (30.4) | 38 (48.1) | |
| Diagnosis | ||||
| Stable CAD | 350 (83.1) | 288 (84.2) | 62 (78.5) | 0.243 | 
| Acute coronary syndrome | 71 (16.9) | 54 (15.8) | 17 (21.5) | |
| Prior myocardial infarction | 155 (36.8) | 106 (31.0) | 49 (62.0) | < 0.001 | 
| Prior PCI | 209 (49.6) | 148 (43.3) | 61 (77.2) | < 0.001 | 
| Prior CABG | 22 (5.2) | 20 (5.8) | 2 (2.5) | 0.397 | 
| Hypertension | 266 (63.2) | 210 (61.4) | 56 (70.9) | 0.122 | 
| Dyslipidemia | 178 (42.3) | 140 (40.9) | 38 (48.1) | 0.257 | 
| Diabetes mellitus | 218 (51.8) | 172 (50.3) | 46 (58.2) | 0.214 | 
| Stroke | 21 (5.0) | 20 (5.8) | 1 (1.3) | 0.147 | 
| Current smoking | 56 (13.3) | 35 (10.2) | 21 (26.6) | < 0.001 | 
| Serum creatinine, mg/dL | 1.33 [1.22, 1.56] | 1.33 [1.20, 1.52] | 1.36 [1.27, 1.62] | 0.057 | 
| eGFR, mL/min/1.73 m2 | 38.4 [32.9, 42.3] | 38.5 [32.6, 42.4] | 36.9 [33.1, 41.8] | 0.368 | 
| GFR category | ||||
| 3b (30 ≤ eGFR < 45) | 352 (83.6) | 284 (83.0) | 68 (86.1) | 0.783 | 
| 4 (15 ≤ eGFR < 30) | 64 (15.2) | 54 (15.8) | 10 (12.6) | |
| 5 (eGFR < 15) | 5 (1.2) | 4 (1.2) | 1 (1.3) | |
| Hemoglobin A1c, % | 6.3 [5.8, 6.9] | 6.3 [5.7, 7.0] | 6.4 [6.0, 6.9] | 0.109 | 
| Low-density lipoprotein cholesterol, mg/dL | 86 [71, 107] | 87 [72, 108] | 82 [70, 103] | 0.301 | 
| Hemoglobin, g/dL | 11.8 [10.5, 13.4] | 11.8 [10.5, 13.4] | 12.1 [10.9, 13.5] | 0.375 | 
| C-reactive protein, mg/dL | 0.14 [0.05, 0.42] | 0.13 [0.05, 0.40] | 0.15 [0.06, 0.53] | 0.180 | 
| NT-proBNP, pg/mL | 864.5 [279.8, 3471.3] | 991.0 [288.3, 3700.0] | 633.0 [177.3, 1775.5] | 0.099 | 
| LVEF, % | 57 [44, 66] | 58 [44, 66] | 52 [43, 63] | 0.140 | 
| Mehran risk score | 8 [6, 11] | 8 [6, 11] | 8 [7, 11] | 0.710 | 
| Catheterization procedure | ||||
| Total agent volume, mL | 150.0 [103.0, 226.0] | 133.0 [92.0, 192.3] | 207.0 [167.5, 271.8] | < 0.001 | 
| Total contrast volume, mL | 135.0 [95.0, 193.0] | 133.0 [92.0, 192.3] | 140.0 [102.0, 195.0] | 0.618 | 
| LMWD volume, mL | 0.0 [0.0, 0.0] | 0.0 [0.0, 0.0] | 67.6 [43.3, 86.0] | < 0.001 | 
| OCT | 79 (40.6) | 92 (26.9) | 79 (100.0) | < 0.001 | 
| Renal function post-procedure | ||||
| ΔCre within 5 d, mg/dL | −0.01 [-0.11, 0.13] | 0.00 [-0.10, 0.14] | −0.03 [-0.14, 0.12] | 0.414 | 
| ΔCre at 1 mo, mg/dL | −0.01 [-0.15, 0.11] | -0.01 [-0.16, 0.11] | -0.01 [-0.13, 0.09] | 0.686 | 
| ΔCre at 1 yr, mg/dL | 0.01 [-0.13, 0.18] | 0.00 [-0.14, 0.16] | 0.07 [-0.04, 0.34] | 0.004 | 
| Acute kidney injury | 51 (12.1) | 42 (12.3) | 9 (11.4) | 1.000 | 
| Worsening renal function (ΔCre ≥ 0.3 mg/dL/1 yr) | 80 (19.0) | 58 (17.0) | 22 (27.8) | 0.039 | 
            Table 2 Patients’ characteristics and renal function (matched cohort)
        
    | Total (n = 150) | Control (n = 75) | LMWD (n = 75) | P value | |
| Sex | ||||
| Male | 119 (79.3) | 61 (81.3) | 58 (77.3) | 0.687 | 
| Female | 31 (20.7) | 14 (18.7) | 17 (22.7) | |
| Age, yr | 75.0 [67.5, 80.0] | 75.0 [69.0, 80.0] | 74.0 [67.0, 79.5] | 0.643 | 
| Body mass index, kg/m2 | 23.7 [21.0, 25.9] | 23.0 [20.8, 25.4] | 24.5 [21.3, 26.8] | 0.030 | 
| Procedure | ||||
| Coronary angiography | 84 (56.0) | 43 (57.3) | 41 (54.7) | 0.869 | 
| PCI | 66 (44.0) | 32 (42.7) | 34 (45.3) | |
| Diagnosis | ||||
| Stable CAD | 121 (80.7) | 61 (81.3) | 60 (80.0) | 1.000 | 
| Acute coronary syndrome | 29 (19.3) | 14 (18.7) | 15 (20.0) | |
| Prior myocardial infarction | 77 (51.3) | 30 (40.0) | 47 (62.7) | 0.009 | 
| Prior PCI | 93 (62.0) | 34 (45.3) | 59 (78.7) | < 0.001 | 
| Prior CABG | 4 (2.7) | 2 (2.7) | 2 (2.7) | 1.000 | 
| Hypertension | 98 (65.3) | 45 (60.0) | 53 (70.7) | 0.230 | 
| Dyslipidemia | 63 (42.0) | 28 (37.3) | 35 (46.7) | 0.321 | 
| Diabetes mellitus | 81 (54.0) | 37 (49.3) | 44 (58.7) | 0.326 | 
| Stroke | 5 (3.3) | 4 (5.3) | 1 (1.3) | 0.367 | 
| Current smoking | 29 (19.3) | 9 (12.0) | 20 (26.7) | 0.037 | 
| Serum creatinine, mg/dL | 1.36 [1.25, 1.63] | 1.37 [1.26, 1.71] | 1.35 [1.25, 1.61] | 0.612 | 
| eGFR, mL/min/1.73 m2 | 37.6 [32.8, 42.0] | 38.0 [31.0, 42.2] | 37.0 [33.2, 41.8] | 0.949 | 
| GFR category | ||||
| 3b (30 ≤ eGFR < 45) | 125 (83.3) | 59 (78.7) | 66 (88.0) | 0.189 | 
| 4 (15 ≤ eGFR < 30) | 25 (16.7) | 16 (21.3) | 9 (12.0) | |
| 5 (eGFR < 15) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Hemoglobin A1c, % | 6.3 [5.9, 6.9] | 6.1 [5.7, 6.9] | 6.5 [6.0, 7.0] | 0.058 | 
| Low-density lipoprotein cholesterol, mg/dL | 87 [70, 108] | 88 [72, 114] | 81 [70, 103] | 0.155 | 
| Hemoglobin, g/dL | 11.8 [10.5, 13.4] | 11.5 [10.3, 13.5] | 12.1 [10.9, 13.3] | 0.230 | 
| C-reactive protein, mg/dL | 0.14 [0.05, 0.46] | 0.12 [0.05, 0.35] | 0.15 [0.06, 0.53] | 0.320 | 
| NT-proBNP, pg/mL | 835.5 [244.8, 3265.3] | 1560.0 [270.0, 4268.5] | 632.0 [175.0, 1679.5] | 0.076 | 
| LVEF, % | 53 [43, 64] | 56 [44, 64] | 52 [43, 63] | 0.697 | 
| Mehran risk score | 8 [7, 11] | 8 [7, 11] | 8 [7, 11] | 0.548 | 
| Catheterization procedure | ||||
| Total agent volume, mL | 174.1 [120.0, 244.8] | 130.0 [88.0, 196.5] | 209.7 [170.1, 271.8] | < 0.001 | 
| Total contrast volume, mL | 138.0 [97.5, 200.0] | 130.0 [88.0, 196.5] | 142.0 [104.5, 200.0] | 0.408 | 
| LMWD volume, mL | 7.6 [0.0, 68.2] | 0.0 [0.0, 0.0] | 68.5 [43.9, 86.0] | < 0.001 | 
| OCT | 95 (63.3) | 20 (26.7) | 75 (100.0) | < 0.001 | 
| Renal function post-procedure | ||||
| ΔCre within 5 d, mg/dL | -0.03 [-0.15, 0.13] | -0.04 [-0.15, 0.14] | -0.03 [-0.14, 0.10] | 0.848 | 
| ΔCre at 1 mo, mg/dL | -0.03 [-0.17, 0.09] | -0.06 [-0.23, 0.10] | -0.02 [-0.14, 0.08] | 0.276 | 
| ΔCre at 1 yr, mg/dL | 0.01 [-0.14, 0.19] | -0.04 [-0.23, 0.08] | 0.06 [-0.06, 0.29] | 0.001 | 
| Acute kidney injury | 14 (9.3) | 7 (9.3) | 7 (9.3) | 1.000 | 
| Worsening renal function (ΔCre ≥ 0.3 mg/dL/1 yr) | 28 (18.7) | 9 (12.0) | 19 (25.3) | 0.059 | 
            Table 3 Univariable and multivariable logistic regression model for predicting worsening renal function (ΔCre ≥ 0.3 mg/dL/1-year) in matched cohort
        
    | Variable | Univariable | Multivariable | ||||||
| OR | 95%CI lower limit | 95%CI upper limit | P value | OR | 95%CI lower limit | 95%CI upper limit | P value | |
| Female | 1.72 | 0.68 | 4.39 | 0.256 | ||||
| Age | 0.96 | 0.92 | 0.99 | 0.036 | Not selected | |||
| Body mass index, kg/m2 | 1.02 | 0.92 | 1.13 | 0.759 | ||||
| PCI | 1.61 | 0.70 | 3.67 | 0.260 | ||||
| Acute coronary syndrome | 1.92 | 0.75 | 4.95 | 0.175 | ||||
| Prior myocardial infarction | 1.33 | 0.58 | 3.05 | 0.496 | ||||
| Prior PCI | 1.68 | 0.69 | 4.11 | 0.258 | ||||
| Hypertension | 0.95 | 0.40 | 2.23 | 0.897 | ||||
| Diabetes mellitus | 2.04 | 0.86 | 4.87 | 0.107 | ||||
| Stroke | 1.09 | 0.12 | 10.20 | 0.938 | ||||
| Current smoking | 1.17 | 0.43 | 3.22 | 0.756 | ||||
| eGFR < 38.4 mL/min/1.73 m2 | 4.18 | 1.58 | 11.00 | 0.004 | 4.27 | 1.59 | 11.40 | 0.004 | 
| LVEF, % | 0.98 | 0.95 | 1.01 | 0.220 | ||||
| Mehran risk score | 1.07 | 0.98 | 1.17 | 0.127 | ||||
| Total agent volume, mL | 1.00 | 0.99 | 1.01 | 0.533 | ||||
| Total contrast volume, mL | 0.99 | 0.99 | 1.01 | 0.776 | ||||
| LMWD volume ≥ 52 mL | 2.76 | 1.19 | 6.37 | 0.018 | 2.83 | 1.18 | 6.76 | 0.019 | 
- Citation: Misawa T, Sugiyama T, Kanaji Y, Hoshino M, Yamaguchi M, Hada M, Nagamine T, Nogami K, Yasui Y, Usui E, Lee T, Yonetsu T, Sasano T, Kakuta T. Low-molecular-weight dextran for optical coherence tomography may not be protective against kidney injury in patients with renal insufficiency. World J Nephrol 2021; 10(2): 8-20
- URL: https://www.wjgnet.com/2220-6124/full/v10/i2/8.htm
- DOI: https://dx.doi.org/10.5527/wjn.v10.i2.8

 
         
                         
                 
                 
                 
                 
                 
                         
                         
                        